Vildagliptin and caloric restriction for cardioprotection in pre-diabetic rats

Journal of Endocrinology

Volumn 232, Issue 2, 2017, Pages 189-204

  Tanajak, Pongpan ^a,b   Pintana, Hiranya ^a,b   Siri Angkul, Natthaphat ^a,b   Khamseekaew, Juthamas ^a,b   Apaijai, Nattayaporn ^a,b   Chattipakorn, Siriporn C ^a,b   Chattipakorn, Nipon ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Apoptosis; Caloric restriction; Cardiac function; DPP 4 inhibitor; Fatty acid oxidation; FGF21 sensitivity; Insulin resistance; Mitochondria; Obesity

Indexed keywords

FATTY ACID; FIBROBLAST GROWTH FACTOR 21; INSULIN; VILDAGLIPTIN; ADAMANTANE; CARDIOTONIC AGENT; FIBROBLAST GROWTH FACTOR; GLUCOSE BLOOD LEVEL; NITRILE; PYRROLIDINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALORIC RESTRICTION; CONTROLLED STUDY; FATTY ACID OXIDATION; HEART; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HEART RATE VARIABILITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAPERITONEAL FAT; LIPID DIET; MALE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BODY WEIGHT; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HEART MITOCHONDRION; HEART RATE; IMPAIRED GLUCOSE TOLERANCE; INTRAABDOMINAL FAT; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ADAMANTANE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CALORIC RESTRICTION; CARDIOTONIC AGENTS; DIET, HIGH-FAT; FIBROBLAST GROWTH FACTORS; HEART RATE; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; MALE; MITOCHONDRIA, HEART; NITRILES; OXIDATIVE STRESS; PREDIABETIC STATE; PYRROLIDINES; RATS; RATS, WISTAR; VENTRICULAR FUNCTION, LEFT;

EID: 85011977227     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-16-0406     Document Type: Article

References (64)

1. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D & Schweizer A 2004 Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 89 2078-2084. (doi:10.1210/jc.2003-031907)
2. Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE & Foley JE 2011 Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes, Obesity and Metabolism 13 775-783. (doi:10.1111/j.1463-1326.2011.01414.x)
3. Apaijai N, Pintana H, Chattipakorn SC & Chattipakorn N 2012 Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet. Endocrinology 153 3878-3885. (doi:10.1210/en.2012-1262)
4. Apaijai N, Pintana H, Chattipakorn SC & Chattipakorn N 2013 Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats. British Journal of Pharmacology 169 1048-1057. (doi:10.1111/bph.12176)
5. Apaijai N, Chinda K, Palee S, Chattipakorn S & Chattipakorn N 2014 Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obeseinsulin resistant rats. PLoS ONE 9 e102374. (doi:10.1371/journal. pone.0102374)
6. Aydin C & Gordon CJ 2013 Thermoregulatory, cardiovascular, and metabolic responses to mild caloric restriction in the Brown Norway rat. Physiological Reports 1 e00016. (doi:10.1002/phy2.16)
7. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE & Wang PR 2005 Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. Journal of Pharmacology and Experimental Therapeutics 315 688-695. (doi:10.1124/jpet.105.087064)
8. Chattipakorn N, Incharoen T, Kanlop N & Chattipakorn S 2007 Heart rate variability in myocardial infarction and heart failure. International Journal of Cardiology 120 289-296. (doi:10.1016/j.ijcard.2006.11.221)
9. Chau MD, Gao J, Yang Q, Wu Z & Gromada J 2010 Fibroblast growth factor 21 regulates energy metabolism by activating the AMPKSIRT1-PGC-1alpha pathway. PNAS 107 12553-12558. (doi:10.1073/pnas.1006962107)
10. Chinda K, Palee S, Surinkaew S, Phornphutkul M, Chattipakorn S & Chattipakorn N 2013 Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. International Journal of Cardiology 167 451-457. (doi:10.1016/j.ijcard.2012.01.011)
11. Chinda K, Sanit J, Chattipakorn S & Chattipakorn N 2014 Dipeptidyl peptidase-4 inhibitor reduces infarct size and preserves cardiac function via mitochondrial protection in ischaemia-reperfusion rat heart. Diabetes and Vascular Disease Research 11 75-83. (doi:10.1177/1479164113516134)
12. Christensen M, Vedtofte L, Holst JJ, Vilsboll T & Knop FK 2011 Glucosedependent insulinotropic polypeptide: a bifunctional glucosedependent regulator of glucagon and insulin secretion in humans. Diabetes 60 3103-3109. (doi:10.2337/db11-0979)
13. Cong WT, Ling J, Tian HS, Ling R, Wang Y, Huang BB, Zhao T, Duan YM, Jin LT & Li XK 2013 Proteomic study on the protective mechanism of fibroblast growth factor 21 to ischemia-reperfusion injury. Canadian Journal of Physiology and Pharmacology 91 973-984. (doi:10.1139/cjpp-2012-0441)
14. Dolinsky VW, Morton JS, Oka T, Robillard-Frayne I, Bagdan M, Lopaschuk GD, Des Rosiers C, Walsh K, Davidge ST & Dyck JR 2010 Calorie restriction prevents hypertension and cardiac hypertrophy in the spontaneously hypertensive rat. Hypertension 56 412-421. (doi:10.1161/HYPERTENSIONAHA.110.154732)
15. Farngren J, Persson M, Schweizer A, Foley JE & Ahren B 2012 Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. Journal of Clinical Endocrinology and Metabolism 97 3799-3806. (doi:10.1210/jc.2012-2332)
16. Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L & DiPetrillo K 2008 Validation of volume-pressure recording tail-cuff blood pressure measurements. American Journal of Hypertension 21 1288-1291. (doi:10.1038/ajh.2008.301)
17. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS & Maratos-Flier E 2010 Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 59 2781-2789. (doi:10.2337/db10-0193)
18. Fontana L, Meyer TE, Klein S & Holloszy JO 2004 Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. PNAS 101 6659-6663. (doi:10.1073/pnas.0308291101)
19. Friedewald WT, Levy RI & Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18 499-502.
20. Gauthier MS, Favier R & Lavoie JM 2006 Time course of the development of non-alcoholic hepatic steatosis in response to high-fat diet-induced obesity in rats. British Journal of Nutrition 95 273-281. (doi:10.1079/BJN20051635)
21. Hwang LL, Wang CH, Li TL, Chang SD, Lin LC, Chen CP, Chen CT, Liang KC, Ho IK, Yang WS, et al. 2010 Sex differences in highfat diet-induced obesity, metabolic alterations and learning, and synaptic plasticity deficits in mice. Obesity 18 463-469. (doi:10.1038/oby.2009.273)
22. Inthachai T, Lekawanvijit S, Kumfu S, Apaijai N, Pongkan W, Chattipakorn SC & Chattipakorn N 2015 Dipeptidyl peptidase-4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction. Experimental Physiology 100 667-679. (doi:10.1113/EP085108)
23. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R & Matthews DR 2015 Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38 140-149. (doi:10.2337/dc14-2441)
24. Itoh N & Ornitz DM 2011 Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. Journal of Biochemistry 149 121-130. (doi:10.1093/jb/mvq121)
25. Joki Y, Ohashi K, Yuasa D, Shibata R, Ito M, Matsuo K, Kambara T, Uemura Y, Hayakawa S, Hiramatsu-Ito M, et al. 2015 FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochemical and Biophysical Research Communications 459 124-130. (doi:10.1016/j. bbrc.2015.02.081)
26. Kharitonenkov A 2009 FGFs and metabolism. Current Opinion in Pharmacology 9 805-810. (doi:10.1016/j.coph.2009.07.001)
27. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG & NC3Rs Reporting Guidelines Working Group 2010 Animal research: reporting in vivo experiments: the ARRIVE guidelines. British Journal of Pharmacology 160 1577-1579. (doi:10.1111/j.1476-5381.2010.00872.x)
28. Liu SQ, Tefft BJ, Roberts DT, Zhang LQ, Ren Y, Li YC, Huang Y, Zhang D, Phillips HR & Wu YH 2012 Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia. American Journal of Physiology: Heart and Circulatory Physiology 303 H1446-H1458. (doi:10.1152/ajpheart.00362.2012)
29. Liu SQ, Roberts D, Kharitonenkov A, Zhang B, Hanson SM, Li YC, Zhang LQ & Wu YH 2013 Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Scientific Reports 3 2767. (doi:10.1038/srep02767)
30. Lu Y, Liu JH, Zhang LK, Du J, Zeng XJ, Hao G, Huang J, Zhao DH, Wang GZ & Zhang YC 2010 Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cells. Chinese Medical Journal 123 3417-3421. (doi:10.3760/cma.j.issn. 0366-6999.2010.23.008)
31. Maeda S, Matsui T & Yamagishi S 2012 Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats. International Journal of Cardiology 158 171-173. (doi:10.1016/j. ijcard.2012.04.087)
32. Manco M, Calvani M & Mingrone G 2004 Effects of dietary fatty acids on insulin sensitivity and secretion. Diabetes, Obesity and Metabolism 6 402-413. (doi:10.1111/j.1462-8902.2004.00356.x)
33. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ & Foley JE 2005 Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 90 4888-4894. (doi:10.1210/jc.2004-2460)
34. Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE & Nauck MA 2003 Gastric inhibitory polypeptide (GIP) dosedependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46 798-801. (doi:10.1007/s00125-003-1103-y)
35. Momiyama Y, Suzuki Y, Ohtomo M, Atsumi Y, Matsuoka K, Ohsuzu F & Kimura M 2002 Cardiac autonomic nervous dysfunction in diabetic patients with a mitochondrial DNA mutation: assessment by heart rate variability. Diabetes Care 25 2308-2313. (doi:10.2337/diacare.25.12.2308)
36. Niemann B, Chen Y, Issa H, Silber RE & Rohrbach S 2010 Caloric restriction delays cardiac ageing in rats: role of mitochondria. Cardiovascular Research 88 267-276. (doi:10.1093/cvr/cvq273)
37. Ong KL, Januszewski AS, O'Connell R, Jenkins AJ, Xu A, Sullivan DR, Barter PJ, Hung WT, Scott RS, Taskinen MR, et al. 2015 The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia 58 464-473. (doi:10.1007/s00125-014-3458-7)
38. Park S, Komatsu T, Hayashi H, Yamaza H, Chiba T, Higami Y, Kuramoto K & Shimokawa I 2006 Calorie restriction initiated at middle age improved glucose tolerance without affecting age-related impairments of insulin signaling in rat skeletal muscle. Experimental Gerontology 41 837-845. (doi:10.1016/j.exger.2006.06.055)
39. Patel V, Adya R, Chen J, Ramanjaneya M, Bari MF, Bhudia SK, Hillhouse EW, Tan BK & Randeva HS 2014 Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PLoS ONE 9 e87102. (doi:10.1371/journal.pone.0087102)
40. Pipatpiboon N, Pratchayasakul W, Chattipakorn N & Chattipakorn SC 2012 PPARgamma agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology 153 329-338. (doi:10.1210/en.2011-1502)
41. Pipatpiboon N, Pintana H, Pratchayasakul W, Chattipakorn N & Chattipakorn SC 2013 DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. European Journal of Neuroscience 37 839-849. (doi:10.1111/ejn.12088)
42. Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, Gabrielli LA, Sitges M, Giralt M, van Bilsen M, et al. 2013 Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nature Communications 4 2019. (doi:10.1038/ncomms3019)
43. Planavila A, Redondo-Angulo I, Ribas F, Garrabou G, Casademont J, Giralt M & Villarroya F 2014 Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovascular Research 106 19-31. (doi:10.1093/cvr/cvu263)
44. Pongchaidecha A, Lailerd N, Boonprasert W & Chattipakorn N 2009 Effects of curcuminoid supplement on cardiac autonomic status in high-fat-induced obese rats. Nutrition 25 870-878. (doi:10.1016/j. nut.2009.02.001)
45. Pongkan W, Pintana H, Jaiwongkam T, Kredphoo S, Sivasinprasasn S, Chattipakorn SC & Chattipakorn N 2016 Vildagliptin reduces cardiac ischemic-reperfusion injury in obese orchiectomized rats. Journal of Endocrinology 231 81-95. (doi:10.1530/JOE-16-0232)
46. Pratchayasakul W, Kerdphoo S, Petsophonsakul P, Pongchaidecha A, Chattipakorn N & Chattipakorn SC 2011 Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone. Life Science 88 619-627. (doi:10.1016/j. lfs.2011.02.003)
47. Pratchayasakul W, Chattipakorn N & Chattipakorn SC 2014 Estrogen restores brain insulin sensitivity in ovariectomized non-obese rats, but not in ovariectomized obese rats. Metabolism 63 851-859. (doi:10.1016/j.metabol.2014.03.009)
48. Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M, Lu Z, Gao M, Bao Y & Jia W 2013 Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovascular Diabetology 12 124. (doi:10.1186/1475-2840-12-124)
49. Smaili SS, Hsu YT, Sanders KM, Russell JT & Youle RJ 2001 Bax translocation to mitochondria subsequent to a rapid loss of mitochondrial membrane potential. Cell Death and Differentiation 8 909-920. (doi:10.1038/sj.cdd.4400889)
50. Surinkaew S, Kumphune S, Chattipakorn S & Chattipakorn N 2013 Inhibition of p38 MAPK during ischemia, but not reperfusion, effectively attenuates fatal arrhythmia in ischemia/reperfusion heart. Journal of Cardiovascular Pharmacology 61 133-141. (doi:10.1097/FJC.0b013e318279b7b1)
51. Takatsu M, Nakashima C, Takahashi K, Murase T, Hattori T, Ito H, Murohara T & Nagata K 2013 Calorie restriction attenuates cardiac remodeling and diastolic dysfunction in a rat model of metabolic syndrome. Hypertension 62 957-965. (doi:10.1161/HYPERTENSIONAHA.113.02093)
52. Tan BK, Hallschmid M, Adya R, Kern W, Lehnert H & Randeva HS 2011 Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity. Diabetes 60 2758-2762. (doi:10.2337/db11-0672)
53. Tanajak P, Chattipakorn SC & Chattipakorn N 2015 Effects of fibroblast growth factor 21 on the heart. Journal of Endocrinology 227 R13-R30. (doi:10.1530/JOE-15-0289)
54. Tanajak P, Sa-Nguanmoo P, Wang X, Liang G, Li X, Jiang C, Chattipakorn SC & Chattipakorn N 2016 Fibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homoeostasis and structural changes in pre-diabetic rats. Acta Physiologica 217 287-299. (doi:10.1111/apha.12698)
55. Thummasorn S, Kumfu S, Chattipakorn S & Chattipakorn N 2011 Granulocyte-colony stimulating factor attenuates mitochondrial dysfunction induced by oxidative stress in cardiac mitochondria. Mitochondrion 11 457-466. (doi:10.1016/j.mito.2011.01.008)
56. Wente W, Efanov AM, Brenner M, Kharitonenkov A, Koster A, Sandusky GE, Sewing S, Treinies I, Zitzer H & Gromada J 2006 Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55 2470-2478. (doi:10.2337/db05-1435)
57. Wilsey J & Scarpace PJ 2004 Caloric restriction reverses the deficits in leptin receptor protein and leptin signaling capacity associated with diet-induced obesity: role of leptin in the regulation of hypothalamic long-form leptin receptor expression. Journal of Endocrinology 181 297-306. (doi:10.1677/joe.0.1810297)
58. Wu X, Qi YF, Chang JR, Lu WW, Zhang JS, Wang SP, Cheng SJ, Zhang M, Fan Q, Lv Y, et al. 2014 Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stressmediated apoptosis in apoE mice. Heart and Vessels 30 657-668. (doi:10.1007/s00380-014-0557-9)
59. Wycherley TP, Brinkworth GD, Noakes M, Buckley JD & Clifton PM 2008 Effect of caloric restriction with and without exercise training on oxidative stress and endothelial function in obese subjects with type 2 diabetes. Diabetes, Obesity and Metabolism 10 1062-1073. (doi:10.1111/j.1463-1326.2008.00863.x)
60. Xu J, Stanislaus S, Chinookoswong N, Lau YY, Hager T, Patel J, Ge H, Weiszmann J, Lu SC, Graham M, et al. 2009 Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models-association with liver and adipose tissue effects. American Journal of Physiology: Endocrinology and Metabolism 297 E1105-E1114. (doi:10.1152/ajpendo.00348.2009)
61. Yan X, Chen J, Zhang C, Zhou S, Zhang Z, Chen J, Feng W, Li X & Tan Y 2015 FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation. Journal of Cellular and Molecular Medicine 19 1557-1568. (doi:10.1111/jcmm.12530)
62. Yin M, Sillje HH, Meissner M, van Gilst WH & de Boer RA 2011 Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of postmyocardial infarction heart failure. Cardiovascular Diabetology 10 85. (doi:10.1186/1475-2840-10-85)
63. Yu Y, Bai F, Liu Y, Yang Y, Yuan Q, Zou D, Qu S, Tian G, Song L, Zhang T, et al. 2015 Fibroblast growth factor (FGF21) protects mouse liver against D-galactose-induced oxidative stress and apoptosis via activating Nrf2 and PI3K/Akt pathways. Molecular and Cellular Biochemistry 403 287-299. (doi:10.1007/s11010-015-2358-6)
64. Zhang C, Huang Z, Gu J, Yan X, Lu X, Zhou S, Wang S, Shao M, Zhang F, Cheng P, et al. 2015 Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signalregulated kinase 1/2-dependent signalling pathway. Diabetologia 58 1937-1948. (doi:10.1007/s00125-015-3630-8)